Seroprotection Rate (titer ≥ 1/40) | Seroconversion Rate, % (95% CI) | |||
---|---|---|---|---|
N | Before Immunization, % (95% CI) | After Immunization, % (95% CI) | ||
Control | 91 | 20.9 (12.6–29.3) | 95.6 (91.4–99.8) | 95.6 (91.4–99.8) |
JARD | 237 | 22.4 (17.1–27.7) | 81.4 (76.5–86.4)* | 74.3 (68.7–79.9)* |
JSLE | 99 | 20.2 (12.3–28.1) | 73.7 (65.0–82.4)* | 63.6 (54.1–73.1)* |
JIA | 93 | 20.4 (12.2–28.6) | 88.2 (81.6–94.8) | 82.8 (75.1–90.5)* |
JDM | 18 | 38.9 (16.4–61.4) | 83.3 (66.1–100.5) | 77.8 (58.6–97.0)* |
JScl | 11 | 27.3 (1.0–53.6) | 90.9 (73.9–107.9) | 90.9 (73.9–107.9) |
Primary vasculitis | 16 | 25.0 (13.8–46.2) | 81.3 (62.2–100.4) | 75 (53.8–96.2)* |
↵* p < 0.05. JARD: juvenile autoimmune rheumatic diseases; JSLE: juvenile systemic lupus erythematosus; JIA: juvenile idiopathic arthritis; JDM: juvenile dermatomyositis; JScl: juvenile scleroderma.